Orforglipron vs Semaglutide

How they differ

Each row below repeats what the two profiles cite. It is not a ranking or a recommendation.

Side by side

TopicOrforglipronSemaglutide
What it is

Not a peptide: a small molecule often looked up alongside peptides7

A synthetic small-molecule, nonpeptide agonist of the GLP-1 receptor, the active ingredient of Foundayo.2,7

A GLP-1 receptor agonist. The Wegovy label describes semaglutide as a GLP-1 analogue with 94% sequence similarity to human GLP-1.3

FDA status

FDA-approved

FDA-approved as Foundayo for weight reduction in adults1,2

FDA-approved. Drugs@FDA lists Foundayo with an original approval date of April 1, 2026. The label has a boxed warning about the risk of thyroid C-cell tumors.1,2

Is orforglipron FDA-approved?

FDA-approved

FDA-approved as Ozempic, Rybelsus and Wegovy3,4,5,6

FDA-approved. Drugs@FDA lists Ozempic (first approved December 5, 2017), Rybelsus (September 20, 2019) and Wegovy (June 4, 2021). The Wegovy label carries a boxed warning about thyroid C-cell tumors seen in rodents.3,4,5,6

Is semaglutide FDA-approved?

HHS compounding policy, October 30, 2026

Not among the six peptides the policy lists.8

Not among the six peptides the policy lists.8

FDA compounding safety-risk page

Not addressed in this profile’s sources.

Not addressed in this profile’s sources.

Kinds of studies cited

Large randomized human trials

  • Large randomized human trial ATTAIN-1 (NCT05869903): a 72-week randomized, double-blind, placebo-controlled trial in 3,127 adults with obesity but without diabetes, in which average weight loss was 7.5% to 11.2% depending on strength, compared with 2.1% on placebo.2,7
  • Large randomized human trial Trial 2 (NCT05872620): a 72-week randomized, double-blind, placebo-controlled trial in 1,613 adults with overweight or obesity and type 2 diabetes, described in the label.2

Large randomized human trials

  • Large randomized human trial A double-blind, placebo-controlled cardiovascular trial (NCT03574597) that randomized 17,604 adults aged 45 or older with established cardiovascular disease and obesity or overweight, without diabetes. The label reports a hazard ratio of 0.80 for major adverse cardiovascular events.3
  • Large randomized human trial A 68-week randomized, double-blind, placebo-controlled weight trial (NCT03548935) in 1,961 adults with obesity, or overweight with a weight-related condition, that excluded type 2 diabetes. It is one of several weight trials the label describes.3
  • Large randomized human trial A randomized, double-blind, placebo-controlled MASH trial (NCT04822181) whose week-72 analysis included 800 adults with moderate to advanced liver fibrosis.3
Records collected

25 ClinicalTrials.gov records and 7 PubMed records collected

140 ClinicalTrials.gov records and 108 PubMed records collected

Area of study

Metabolic and weight2

Metabolic and weight, Heart and blood vessels, Liver3

Latest dated events
  1. DailyMed publishes version 10 of the Foundayo label, the version cited here.2
  2. FDA approves Foundayo, NDA 220934, according to Drugs@FDA.1
  3. The ATTAIN-1 trial of 3,127 adults with obesity is published.7
  1. FDA’s page on unapproved GLP-1 drugs is updated, as shown by its content-current date.9
  2. DailyMed publishes the Wegovy label version cited on this page.3
  3. FDA proposes excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list.10

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    Drugs@FDA: FOUNDAYO (orforglipron calcium), NDA 220934 · original approval April 1, 2026 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 16, 2026

  2. 2
    FOUNDAYO (orforglipron) tablet, film coated · SPL version 10 · published 2026-08-13 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked November 16, 2026

  3. 3
    WEGOVY (semaglutide) injection and tablet · SPL version 19 · published 2026-06-30 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked July 22, 2026

  4. 4
    Drugs@FDA application NDA209637 · original submission status AP · 2017-12-05 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  5. 5
    Drugs@FDA application NDA213051 · original submission status AP · 2019-09-20 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  6. 6
    Drugs@FDA application NDA215256 · original submission status AP · 2021-06-04 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  7. 7
    Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (2025) · PMID 40960239 ↗

    The New England Journal of Medicine · Official source · Source checked November 16, 2026

  8. 8
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  9. 9
    FDA’s concerns with unapproved GLP-1 drugs used for weight loss · content current as of October 1, 2026 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  10. 10
    FDA proposes to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list ↗

    U.S. Food and Drug Administration · Official source · Source checked July 29, 2026